Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

Online supplementary material S4: Meta-analysis

## Comparison 1. Adalimumab versus placebo

Analysis 1.1. Adalimumab 40mg versus placebo in Rheumatoid Arthritis at 52 weeks.

*Analysis 1.2. Adalimumab 40mg versus placebo in Rheumatoid Arthritis at 12 weeks.*

*Analysis 1.3. Adalimumab 40mg versus placebo in Psoriatic Arthritis at 12 weeks.*

Comparison 2. Baricitinib versus placebo

Analysis 2.1. Baricitinib 4mg versus placebo in Rheumatoid Arthritis at 24 weeks.

1

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

RMD Open

Comparison 3. Sarilumab versus placebo

*Analysis 3.1. Sarilumab versus placebo in Rheumatoid Arthritis at 24 weeks.*

Comparison 4. Tocilizumab versus placebo

Analysis 4.1. Tocilizumab versus placebo in Rheumatoid Arthritis at 24 weeks.


2

Comparison 5. Golimumab versus placebo

*Analysis 5.1. Golimumab 100mg versus placebo in Rheumatoid Arthritis at 24 weeks.*

Comparison 6. Tofacitinib versus placebo

Analysis 6.1. Tofacitinib versus placebo in Rheumatoid Arthritis at 12 weeks.

Comparison 7. Secukinumab versus placebo

Analysis 7.1. Secukinumab versus placebo in Spondyloarthritis at 16 weeks.

3

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

Comparison 8. Etanercept versus placebo

Analysis 8.1. Etanercept 50mg versus placebo in Spondyloarthritis at 12 weeks.